Change search
ReferencesLink to record
Permanent link

Direct link
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting
Umeå University, Faculty of Medicine, Department of Community Medicine and Rehabilitation, Geriatric Medicine.
Show others and affiliations
2007 (English)In: Dementia and Geriatric Cognitive Disorders, ISSN 1420-8008, E-ISSN 1421-9824, Vol. 23, no 3, 150-160 p.Article in journal (Refereed) PublishedText
Abstract [en]

Background/Aims: Clinical short- term trails have shownpositive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated.

Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer's disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years.

Results: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% Cl, 3.0-4.7) and the ADAS-cog rise was 8.2 points ( 95% Cl, 6.4-10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points; 95% CI, 14.5-16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment.

Conclusion: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting.

Place, publisher, year, edition, pages
Basel: S. Karger, 2007. Vol. 23, no 3, 150-160 p.
Keyword [en]
Alzheimer's disease, cholinesterase inhibitor, donepezil
National Category
Geriatrics Neurology Psychiatry
URN: urn:nbn:se:umu:diva-118228DOI: 10.1159/000098052ISI: 000244108300003PubMedID: 17312368OAI: diva2:916693
Available from: 2016-04-04 Created: 2016-03-14 Last updated: 2016-04-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Eriksson, StureNäsman, BirgittaEkdahl, Anne
By organisation
Geriatric Medicine
In the same journal
Dementia and Geriatric Cognitive Disorders

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 10 hits
ReferencesLink to record
Permanent link

Direct link